Iqvia (IQV) Issues FY19 Earnings Guidance

Share on StockTwits

Iqvia (NYSE:IQV) issued an update on its FY19 earnings guidance on Wednesday morning. The company provided EPS guidance of $6.20 to $6.40 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.34. The company issued revenue guidance of $10.900 billion to $11.125 billion, compared to the consensus revenue estimate of $11.02 billion.Iqvia also updated its FY 2019 guidance to $6.20-6.40 EPS.

IQV stock traded up $2.36 during midday trading on Friday, hitting $138.50. The stock had a trading volume of 947,801 shares, compared to its average volume of 1,268,367. The stock has a market cap of $27.47 billion, a P/E ratio of 27.05, a price-to-earnings-growth ratio of 1.69 and a beta of 0.81. Iqvia has a 52 week low of $91.57 and a 52 week high of $146.10. The company has a debt-to-equity ratio of 1.57, a current ratio of 1.10 and a quick ratio of 1.10.

Iqvia (NYSE:IQV) last issued its earnings results on Wednesday, May 1st. The medical research company reported $1.53 EPS for the quarter, topping the consensus estimate of $1.41 by $0.12. The firm had revenue of $2.68 billion during the quarter, compared to analysts’ expectations of $2.67 billion. Iqvia had a return on equity of 14.25% and a net margin of 2.49%. Iqvia’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period last year, the business earned $1.34 earnings per share. Equities research analysts anticipate that Iqvia will post 5.86 EPS for the current year.

IQV has been the subject of several recent analyst reports. Goldman Sachs Group upgraded Iqvia from a buy rating to a conviction-buy rating in a research note on Friday, January 11th. Jefferies Financial Group upgraded Iqvia from a hold rating to a buy rating and increased their price objective for the stock from $136.00 to $150.00 in a research note on Friday, January 18th. Piper Jaffray Companies increased their price objective on Iqvia to $148.00 and gave the stock a neutral rating in a research note on Friday, February 15th. UBS Group set a $170.00 price objective on Iqvia and gave the stock a buy rating in a research note on Friday, February 15th. Finally, Barclays reiterated a buy rating and set a $155.00 price objective on shares of Iqvia in a research note on Friday, February 15th. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company. The stock has an average rating of Buy and an average price target of $146.88.

In other news, Director Ronald A. Rittenmeyer sold 3,840 shares of the firm’s stock in a transaction on Tuesday, February 5th. The stock was sold at an average price of $130.00, for a total value of $499,200.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Group Holdings (Sbs) Advis Tpg sold 4,044,480 shares of the firm’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $140.80, for a total value of $569,462,784.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 4,172,538 shares of company stock valued at $587,465,163. 6.00% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “Iqvia (IQV) Issues FY19 Earnings Guidance” was originally reported by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at

About Iqvia

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Story: Conference Calls and Individual Investors

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with's FREE daily email newsletter.